Literature DB >> 2466017

Survival after incomplete resection or exploratory thoracotomy in patients with advanced non small cell lung cancer.

G B Ratto1, F Fabiano, S Rovida, F Baracco, M De Palma.   

Abstract

In order to evaluate the effects of incomplete resection or exploratory thoracotomy on survival, 75 patients with Stage III non small-cell lung cancer (NSCLC) were studied. Twenty-five subjects underwent incomplete resection, 25 had exploratory thoracotomy and 25 patients who were denied surgery served as controls. Standard radio-therapy and chemotherapy regimens were given to most patients. The 2-year survival rates were 14%, 7% and 9% following incomplete resection, exploratory thoracotomy or conservative treatment, respectively. The survival curve was significantly worse in the exploratory thoracotomy group than in the control group (p less than 0.05). Major complications occurred in 2 patients after incomplete resection (bronchopleural fistula; chylothorax) and in 3 patients following surgical exploration (atelectasis). Two post-operative deaths were recorded in the exploratory thoracotomy group. In conclusion, the survival rate at 2 years in patients with Stage III NSCLC is not modified by incomplete or exploratory surgery. Moreover, exploration seems to worsen the outlook of patients during the first 2 years from diagnosis.

Entities:  

Mesh:

Year:  1988        PMID: 2466017

Source DB:  PubMed          Journal:  Ital J Surg Sci        ISSN: 0392-3525


  2 in total

1.  Exploratory thoracotomy and its influence on the survival of patients with lung cancer.

Authors:  Lucka Debevec; Janez Erzen; Andrej Debeljak; Anton Crnjac; Viljem Kovac
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

Review 2.  Is there a survival advantage of incomplete resection of non-small-cell lung cancer that is found to be unresectable at thoracotomy?

Authors:  Keltie Dall; Christopher Ford; Rachael Fisher; Joel Dunning
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.